Alladapt: addressing multiple food allergies simultaneously

Alladapt is creating an oral immunotherapy comprising proteins from multiple food allergens and hoping that gradually increasing the dose will desensitize the immune system.

The idea for Alladapt Immunotherapeutics Inc. came from the lab of co-founder Kari Nadeau, director of Stanford University’s Sean N. Parker Center for Allergy and Asthma Research. Nadeau pioneered the paradigm of “low-and-slow” dosing of multiple proteins to simultaneously desensitize an allergic person to several foods, Alladapt CEO Ashley Dombkowski told BioCentury...